Stock Analysis

Invesco (IVZ) Is Up 8.8% After Premium Preferred Buyback And LGT Tie-Up Has The Bull Case Changed?

  • Earlier this month, Invesco Ltd. agreed to repurchase US$500 million of its 5.9% Series A preferred shares from MassMutual at an 18% premium, while also forming a partnership with LGT Capital Partners to build multi-alternative private markets solutions for U.S. wealth and retirement investors.
  • Together, these steps highlight Invesco’s focus on reshaping its capital structure and deepening its presence in higher-fee private markets offerings.
  • We’ll now explore how this preferred share buyback shapes Invesco’s existing investment narrative around margins, capital allocation, and private markets growth.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Invesco Investment Narrative Recap

To own Invesco, I think you need to believe it can defend margins while repositioning from traditional active products toward higher-fee alternatives and scalable ETF offerings. The US$500 million Series A preferred repurchase modestly tightens the capital structure but does not materially change the near term earnings catalyst, which remains execution on private markets expansion. The biggest current risk is that fee and margin pressure persist as investors continue shifting to lower cost products and competitors.

The new partnership with LGT Capital Partners looks especially relevant here because it directly reinforces Invesco’s push into multi alternative private markets solutions for U.S. wealth and retirement clients. If Invesco can turn that expanded alternatives platform into sustained inflows and better revenue mix, it could help offset ongoing fee compression in traditional active strategies and support the margin story investors are watching most closely right now.

Yet against this opportunity, investors should also be aware that accelerating competition in ETFs and active equities could still...

Read the full narrative on Invesco (it's free!)

Invesco’s narrative projects $4.8 billion revenue and $1.1 billion earnings by 2028. This requires an 8.2% yearly revenue decline and about a $677 million earnings increase from $422.9 million today.

Uncover how Invesco's forecasts yield a $26.38 fair value, in line with its current price.

Exploring Other Perspectives

IVZ 1-Year Stock Price Chart
IVZ 1-Year Stock Price Chart

Four members of the Simply Wall St Community value Invesco between US$8.11 and US$27.61, highlighting how far apart individual views can be. When you set those ranges against the risk of long term fee and margin pressure from the shift toward low cost products, it underlines why it can be useful to compare several independent perspectives before forming your own view.

Explore 4 other fair value estimates on Invesco - why the stock might be worth less than half the current price!

Build Your Own Invesco Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

The New Payments ETF Is Live on NASDAQ:

Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.

Explore how this launch could reshape portfolios

Sponsored Content

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:IVZ

Invesco

A publicly owned investment manager.

Adequate balance sheet average dividend payer.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4034.1% undervalued
22 users have followed this narrative
2 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6089.9% undervalued
22 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.0% undervalued
43 users have followed this narrative
4 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)

Fair Value:US$21.5370.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KI
RKLB logo
KiwiInvest on Rocket Lab ·

Rocket Lab USA Will Ignite a 30% Revenue Growth Journey

Fair Value:US$97.8335.1% undervalued
136 users have followed this narrative
8 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
120 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.7% undervalued
963 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8688.0% undervalued
78 users have followed this narrative
8 users have commented on this narrative
21 users have liked this narrative